STOCK TITAN

BioRestorative Therapies Inc - BRTX STOCK NEWS

Welcome to our dedicated news page for BioRestorative Therapies (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioRestorative Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioRestorative Therapies's position in the market.

Rhea-AI Summary
BioRestorative Therapies aims to provide better treatment options for chronic pain without the need for opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies Inc. (NASDAQ:BRTX) insiders, including Dale Broadrick and CEO Lance Alstodt, demonstrate confidence in the company's future by acquiring shares. Insider buying signals positive outlook and sentiment, providing valuable insights for evaluating potential company performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
Rhea-AI Summary
BioRestorative Therapies Inc. (NASDAQ:BRTX) has been granted a license by the New York State Department of Health to operate as a tissue bank, allowing the processing of mesenchymal stem cells for clinical use. This makes BioRestorative the first facility in New York State licensed to do so, setting it apart from competitors. Mesenchymal Stem Cells have the potential to be used in the development of treatments for various diseases, and BioRestorative is excited about the possibilities this presents for their business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies, Inc. has entered into a definitive agreement for the sale of 685,033 shares of common stock at an offering price of $3.03 per share, resulting in gross proceeds of approximately $2.1 million. The proceeds will be used for clinical trials, pre-clinical research and development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
clinical trial
Rhea-AI Summary
BioRestorative Therapies receives unanimous recommendation from DSMB to continue Phase 2 trial for chronic lumbar disc disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.88%
Tags
clinical trial
-
Rhea-AI Summary
BioRestorative Therapies, Inc. (NASDAQ: BRTX) CEO, Lance Alstodt, has been invited to present at the Healthcare Virtual Conference Part II. The conference will be held from June 20th to June 22nd and will feature presentations and discussions with CEOs and key management. BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Their two core programs focus on the treatment of disc/spine disease and metabolic disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.65%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
conferences
BioRestorative Therapies Inc

Nasdaq:BRTX

BRTX Rankings

BRTX Stock Data

9.13M
3.54M
26.86%
13.81%
0.1%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Melville

About BRTX

biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas